Makoto Ohmiya, Ph.D.
Dr. Ohmiya has worked as a pharmacological researcher in neuroscience and discovered three drug candidates. He has also been engaged in digital therapeutics-related venture investments in the US at Rx+ Business Accelerator Division since 2018. In 2020, he started research on circadian rhythms and has been in his current position since August 2023. He believes in providing newly valuable therapy to patients suffering from illnesses as quickly as possible.
Astellas is seeking partners in this area and would wish to explore the following assets and capabilities
- Candidate molecules for new medicine related to circadian rhythm regulation
- Novel biomarker or the cutting-edge technology to measure circadian rhythms
- Animal model studies of various diseases induced by circadian rhythm misalignment